Laura E. Niklason, M.D., Ph.D., is the President and Chief Executive Officer of Humacyte, Inc., a pioneering regenerative medicine company focused on developing and commercializing acellular tissues to improve patient outcomes. Dr. Niklason's impressive career spans both academia and industry, making her a leading figure in the field of tissue engineering and regenerative medicine. She earned her M.D. and Ph.D. from the University of Chicago, where she completed her residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine. Her academic journey continued at Duke University, where she served as a Professor of Anesthesiology, Biomedical Engineering, and Medicine, and was a renowned researcher in the field of tissue engineering. At Humacyte, Dr. Niklason has been instrumental in advancing the company's mission to develop innovative solutions for vascular trauma and disease. Under her leadership, Humacyte has made significant strides in the development of their flagship product, the Human Acellular Vessel (HAV), which is designed to serve as a bioengineered blood vessel for vascular repair and replacement. The HAV has shown promising results in clinical trials, offering hope for patients with vascular conditions who currently have limited treatment options. Dr. Niklason's visionary approach and dedication to improving patient care have been crucial in positioning Humacyte as a leader in the regenerative medicine space. In addition to her role at Humacyte, Dr. Niklason has received numerous accolades for her contributions to the field of tissue engineering and regenerative medicine. She has authored over 100 peer-reviewed publications and holds more than 50 issued patents, reflecting her commitment to advancing scientific knowledge and innovation. Her leadership extends beyond Humacyte, as she serves on the editorial boards of several prestigious scientific journals and is a member of various professional organizations. Dr. Niklason's expertise, passion, and dedication to improving patient outcomes make her an invaluable asset to Humacyte and the broader regenerative medicine community.